Review





Similar Products

90
Medeor Therapeutics medeor's cellular products
Medeor's Cellular Products, supplied by Medeor Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/product+no/medeor+matrix/nct05010174-1-24-24
Average 90 stars, based on 1 article reviews
medeor's cellular products - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

91
MedChemExpress mif production
APOA5 deficiency results in increased <t>intracellular</t> <t>cholesterol</t> and accelerated tumor progression. (A) Schematic overview of cholesterol homeostasis in a tumor cell, highlighting cholesterol synthesis (HMGCR, HMGCS1, NSDHL), esterification (ACAT1) and efflux (ABCG1). (B) Violin plot comparing cholesterol synthesis flux (determined by flux balance analysis) between TCGA‐LUAD samples with high versus low APOA5 expression. (C‐D) Boxplots showing normalized single‐sample Gene Ste Enrichment Analysis (ssGSEA) scores for (C) cholesterol esterification and (D) cholesterol metabolism in LUAD samples, stratified by high versus low APOA5 expression. (E) Line plot illustrating cholesterol efflux activity scores across TCGA LUAD samples (n = 238) ranked by APOA5 expression level, comparing high versus low APOA5 groups (p = 0.0038). (F‐I) Box plots displaying normalized mRNA expression levels from TCGA‐LUAD patient samples for key cholesterol metabolism genes: (F) HMGCR (p = 4.4e‐05), (G) NSDHL (p = 0.01), (H) ACAT1 (p = 1.5e‐05), and (I) ABCG1 (p = 0.049), comparing low versus high APOA5 expression groups. (J) Relative mRNA expression levels, determined by qPCR, of cholesterol synthesis pathway genes (Hmgcs1, Hmgcr, Nsdhl) in LLC control cells, Apoa5 knockout cells (sgApoa5), and Apoa5 overexpressing cells (OE‐Apoa5). (K) Relative mRNA expression levels (qPCR) of cholesterol esterification gene Acat1 and cholesterol transporter Abca1 in LLC control, sgApoa5, and OE‐Apoa5 cells. (L) Relative mRNA expression levels (qPCR) of cholesterol transporter Abcg1 in LLC control, sgApoa5, and OE‐Apoa5 cells. (M‐O) Total cholesterol levels measured in (M) LLC cell lines (Control, sgApoa5, OE‐Apoa5, OE‐Apoa5/sgApoa5), (N) tumor epithelial cells derived from these cell lines’ mouse models, and (O) serum from C57BL/6J mice bearing these LLC tumors. (P) Intracellular cholesterol concentrations in WT and sgAapoa5 LLC cells treated with vehicle, lovastatin (Lova), or lovastatin together with cholesterol (Lova + Chol). (Q) Relative <t>Mif</t> mRNA levels in WT and sgApoa5 LLC cells following the indicated treatments with lovastatin alone or lovastatin plus cholesterol. (R) MIF concentration in the culture supernatants of WT and sgApoa5 LLC cells following the indicated treatments, as determined by ELISA. (S) Schematic model summarizing the proposed role of APOA5 in regulating cholesterol within tumor cells. (T) Western blot analysis validating APOA5 protein levels in LLC cells: Ctr (control), sg1 and sg2 (Apoa5 knockout using two different sgRNAs), OE (Apoa5 overexpression), Ctr (control for OE/sg1, OE/sg2 comparison), OE/sg1 and OE/sg2 (Apoa5 knockout in Apoa5 overexpressing cells). β‐actin was used as a loading control. (U) Representative images of LLC tumors harvested from C57BL/6J mice on day 21 post‐implantation with Control, sgApoa5 (LLC‐sgApoa5), OE‐Apoa5 (LLC‐OE‐Apoa5), or OE‐Apoa5/sgApoa5 (LLC‐OE‐Apoa5/sgApoa5) cells. (V) Tumor growth curves for the different LLC cell lines implanted in C57BL/6J mice (n = 5 mice per group). P‐values indicated compare each group to the Control.
Mif Production, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/product+no/Apolipoprotein+A-V%2FAPOA5%2C+Mouse/pmc13771656-346-10-41
Average 91 stars, based on 1 article reviews
mif production - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

95
ABclonal Biotechnology anti puromycin rabbit monoclonal antibody
APOA5 deficiency results in increased <t>intracellular</t> <t>cholesterol</t> and accelerated tumor progression. (A) Schematic overview of cholesterol homeostasis in a tumor cell, highlighting cholesterol synthesis (HMGCR, HMGCS1, NSDHL), esterification (ACAT1) and efflux (ABCG1). (B) Violin plot comparing cholesterol synthesis flux (determined by flux balance analysis) between TCGA‐LUAD samples with high versus low APOA5 expression. (C‐D) Boxplots showing normalized single‐sample Gene Ste Enrichment Analysis (ssGSEA) scores for (C) cholesterol esterification and (D) cholesterol metabolism in LUAD samples, stratified by high versus low APOA5 expression. (E) Line plot illustrating cholesterol efflux activity scores across TCGA LUAD samples (n = 238) ranked by APOA5 expression level, comparing high versus low APOA5 groups (p = 0.0038). (F‐I) Box plots displaying normalized mRNA expression levels from TCGA‐LUAD patient samples for key cholesterol metabolism genes: (F) HMGCR (p = 4.4e‐05), (G) NSDHL (p = 0.01), (H) ACAT1 (p = 1.5e‐05), and (I) ABCG1 (p = 0.049), comparing low versus high APOA5 expression groups. (J) Relative mRNA expression levels, determined by qPCR, of cholesterol synthesis pathway genes (Hmgcs1, Hmgcr, Nsdhl) in LLC control cells, Apoa5 knockout cells (sgApoa5), and Apoa5 overexpressing cells (OE‐Apoa5). (K) Relative mRNA expression levels (qPCR) of cholesterol esterification gene Acat1 and cholesterol transporter Abca1 in LLC control, sgApoa5, and OE‐Apoa5 cells. (L) Relative mRNA expression levels (qPCR) of cholesterol transporter Abcg1 in LLC control, sgApoa5, and OE‐Apoa5 cells. (M‐O) Total cholesterol levels measured in (M) LLC cell lines (Control, sgApoa5, OE‐Apoa5, OE‐Apoa5/sgApoa5), (N) tumor epithelial cells derived from these cell lines’ mouse models, and (O) serum from C57BL/6J mice bearing these LLC tumors. (P) Intracellular cholesterol concentrations in WT and sgAapoa5 LLC cells treated with vehicle, lovastatin (Lova), or lovastatin together with cholesterol (Lova + Chol). (Q) Relative <t>Mif</t> mRNA levels in WT and sgApoa5 LLC cells following the indicated treatments with lovastatin alone or lovastatin plus cholesterol. (R) MIF concentration in the culture supernatants of WT and sgApoa5 LLC cells following the indicated treatments, as determined by ELISA. (S) Schematic model summarizing the proposed role of APOA5 in regulating cholesterol within tumor cells. (T) Western blot analysis validating APOA5 protein levels in LLC cells: Ctr (control), sg1 and sg2 (Apoa5 knockout using two different sgRNAs), OE (Apoa5 overexpression), Ctr (control for OE/sg1, OE/sg2 comparison), OE/sg1 and OE/sg2 (Apoa5 knockout in Apoa5 overexpressing cells). β‐actin was used as a loading control. (U) Representative images of LLC tumors harvested from C57BL/6J mice on day 21 post‐implantation with Control, sgApoa5 (LLC‐sgApoa5), OE‐Apoa5 (LLC‐OE‐Apoa5), or OE‐Apoa5/sgApoa5 (LLC‐OE‐Apoa5/sgApoa5) cells. (V) Tumor growth curves for the different LLC cell lines implanted in C57BL/6J mice (n = 5 mice per group). P‐values indicated compare each group to the Control.
Anti Puromycin Rabbit Monoclonal Antibody, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/product+no/Rabbit+Monoclonal+Antibody+Production/pm43022454-142-17-21
Average 95 stars, based on 1 article reviews
anti puromycin rabbit monoclonal antibody - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

99
Gilead Sciences cd19 bcma car t product
APOA5 deficiency results in increased <t>intracellular</t> <t>cholesterol</t> and accelerated tumor progression. (A) Schematic overview of cholesterol homeostasis in a tumor cell, highlighting cholesterol synthesis (HMGCR, HMGCS1, NSDHL), esterification (ACAT1) and efflux (ABCG1). (B) Violin plot comparing cholesterol synthesis flux (determined by flux balance analysis) between TCGA‐LUAD samples with high versus low APOA5 expression. (C‐D) Boxplots showing normalized single‐sample Gene Ste Enrichment Analysis (ssGSEA) scores for (C) cholesterol esterification and (D) cholesterol metabolism in LUAD samples, stratified by high versus low APOA5 expression. (E) Line plot illustrating cholesterol efflux activity scores across TCGA LUAD samples (n = 238) ranked by APOA5 expression level, comparing high versus low APOA5 groups (p = 0.0038). (F‐I) Box plots displaying normalized mRNA expression levels from TCGA‐LUAD patient samples for key cholesterol metabolism genes: (F) HMGCR (p = 4.4e‐05), (G) NSDHL (p = 0.01), (H) ACAT1 (p = 1.5e‐05), and (I) ABCG1 (p = 0.049), comparing low versus high APOA5 expression groups. (J) Relative mRNA expression levels, determined by qPCR, of cholesterol synthesis pathway genes (Hmgcs1, Hmgcr, Nsdhl) in LLC control cells, Apoa5 knockout cells (sgApoa5), and Apoa5 overexpressing cells (OE‐Apoa5). (K) Relative mRNA expression levels (qPCR) of cholesterol esterification gene Acat1 and cholesterol transporter Abca1 in LLC control, sgApoa5, and OE‐Apoa5 cells. (L) Relative mRNA expression levels (qPCR) of cholesterol transporter Abcg1 in LLC control, sgApoa5, and OE‐Apoa5 cells. (M‐O) Total cholesterol levels measured in (M) LLC cell lines (Control, sgApoa5, OE‐Apoa5, OE‐Apoa5/sgApoa5), (N) tumor epithelial cells derived from these cell lines’ mouse models, and (O) serum from C57BL/6J mice bearing these LLC tumors. (P) Intracellular cholesterol concentrations in WT and sgAapoa5 LLC cells treated with vehicle, lovastatin (Lova), or lovastatin together with cholesterol (Lova + Chol). (Q) Relative <t>Mif</t> mRNA levels in WT and sgApoa5 LLC cells following the indicated treatments with lovastatin alone or lovastatin plus cholesterol. (R) MIF concentration in the culture supernatants of WT and sgApoa5 LLC cells following the indicated treatments, as determined by ELISA. (S) Schematic model summarizing the proposed role of APOA5 in regulating cholesterol within tumor cells. (T) Western blot analysis validating APOA5 protein levels in LLC cells: Ctr (control), sg1 and sg2 (Apoa5 knockout using two different sgRNAs), OE (Apoa5 overexpression), Ctr (control for OE/sg1, OE/sg2 comparison), OE/sg1 and OE/sg2 (Apoa5 knockout in Apoa5 overexpressing cells). β‐actin was used as a loading control. (U) Representative images of LLC tumors harvested from C57BL/6J mice on day 21 post‐implantation with Control, sgApoa5 (LLC‐sgApoa5), OE‐Apoa5 (LLC‐OE‐Apoa5), or OE‐Apoa5/sgApoa5 (LLC‐OE‐Apoa5/sgApoa5) cells. (V) Tumor growth curves for the different LLC cell lines implanted in C57BL/6J mice (n = 5 mice per group). P‐values indicated compare each group to the Control.
Cd19 Bcma Car T Product, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/product+no/Yescarta/pmc13747162-191-15-19
Average 99 stars, based on 1 article reviews
cd19 bcma car t product - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

96
New England Biolabs gdna region product
APOA5 deficiency results in increased <t>intracellular</t> <t>cholesterol</t> and accelerated tumor progression. (A) Schematic overview of cholesterol homeostasis in a tumor cell, highlighting cholesterol synthesis (HMGCR, HMGCS1, NSDHL), esterification (ACAT1) and efflux (ABCG1). (B) Violin plot comparing cholesterol synthesis flux (determined by flux balance analysis) between TCGA‐LUAD samples with high versus low APOA5 expression. (C‐D) Boxplots showing normalized single‐sample Gene Ste Enrichment Analysis (ssGSEA) scores for (C) cholesterol esterification and (D) cholesterol metabolism in LUAD samples, stratified by high versus low APOA5 expression. (E) Line plot illustrating cholesterol efflux activity scores across TCGA LUAD samples (n = 238) ranked by APOA5 expression level, comparing high versus low APOA5 groups (p = 0.0038). (F‐I) Box plots displaying normalized mRNA expression levels from TCGA‐LUAD patient samples for key cholesterol metabolism genes: (F) HMGCR (p = 4.4e‐05), (G) NSDHL (p = 0.01), (H) ACAT1 (p = 1.5e‐05), and (I) ABCG1 (p = 0.049), comparing low versus high APOA5 expression groups. (J) Relative mRNA expression levels, determined by qPCR, of cholesterol synthesis pathway genes (Hmgcs1, Hmgcr, Nsdhl) in LLC control cells, Apoa5 knockout cells (sgApoa5), and Apoa5 overexpressing cells (OE‐Apoa5). (K) Relative mRNA expression levels (qPCR) of cholesterol esterification gene Acat1 and cholesterol transporter Abca1 in LLC control, sgApoa5, and OE‐Apoa5 cells. (L) Relative mRNA expression levels (qPCR) of cholesterol transporter Abcg1 in LLC control, sgApoa5, and OE‐Apoa5 cells. (M‐O) Total cholesterol levels measured in (M) LLC cell lines (Control, sgApoa5, OE‐Apoa5, OE‐Apoa5/sgApoa5), (N) tumor epithelial cells derived from these cell lines’ mouse models, and (O) serum from C57BL/6J mice bearing these LLC tumors. (P) Intracellular cholesterol concentrations in WT and sgAapoa5 LLC cells treated with vehicle, lovastatin (Lova), or lovastatin together with cholesterol (Lova + Chol). (Q) Relative <t>Mif</t> mRNA levels in WT and sgApoa5 LLC cells following the indicated treatments with lovastatin alone or lovastatin plus cholesterol. (R) MIF concentration in the culture supernatants of WT and sgApoa5 LLC cells following the indicated treatments, as determined by ELISA. (S) Schematic model summarizing the proposed role of APOA5 in regulating cholesterol within tumor cells. (T) Western blot analysis validating APOA5 protein levels in LLC cells: Ctr (control), sg1 and sg2 (Apoa5 knockout using two different sgRNAs), OE (Apoa5 overexpression), Ctr (control for OE/sg1, OE/sg2 comparison), OE/sg1 and OE/sg2 (Apoa5 knockout in Apoa5 overexpressing cells). β‐actin was used as a loading control. (U) Representative images of LLC tumors harvested from C57BL/6J mice on day 21 post‐implantation with Control, sgApoa5 (LLC‐sgApoa5), OE‐Apoa5 (LLC‐OE‐Apoa5), or OE‐Apoa5/sgApoa5 (LLC‐OE‐Apoa5/sgApoa5) cells. (V) Tumor growth curves for the different LLC cell lines implanted in C57BL/6J mice (n = 5 mice per group). P‐values indicated compare each group to the Control.
Gdna Region Product, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/product+no/EnGen+Sau+Cas9/pm43003089-551-18-28
Average 96 stars, based on 1 article reviews
gdna region product - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

99
New England Biolabs lamp product
APOA5 deficiency results in increased <t>intracellular</t> <t>cholesterol</t> and accelerated tumor progression. (A) Schematic overview of cholesterol homeostasis in a tumor cell, highlighting cholesterol synthesis (HMGCR, HMGCS1, NSDHL), esterification (ACAT1) and efflux (ABCG1). (B) Violin plot comparing cholesterol synthesis flux (determined by flux balance analysis) between TCGA‐LUAD samples with high versus low APOA5 expression. (C‐D) Boxplots showing normalized single‐sample Gene Ste Enrichment Analysis (ssGSEA) scores for (C) cholesterol esterification and (D) cholesterol metabolism in LUAD samples, stratified by high versus low APOA5 expression. (E) Line plot illustrating cholesterol efflux activity scores across TCGA LUAD samples (n = 238) ranked by APOA5 expression level, comparing high versus low APOA5 groups (p = 0.0038). (F‐I) Box plots displaying normalized mRNA expression levels from TCGA‐LUAD patient samples for key cholesterol metabolism genes: (F) HMGCR (p = 4.4e‐05), (G) NSDHL (p = 0.01), (H) ACAT1 (p = 1.5e‐05), and (I) ABCG1 (p = 0.049), comparing low versus high APOA5 expression groups. (J) Relative mRNA expression levels, determined by qPCR, of cholesterol synthesis pathway genes (Hmgcs1, Hmgcr, Nsdhl) in LLC control cells, Apoa5 knockout cells (sgApoa5), and Apoa5 overexpressing cells (OE‐Apoa5). (K) Relative mRNA expression levels (qPCR) of cholesterol esterification gene Acat1 and cholesterol transporter Abca1 in LLC control, sgApoa5, and OE‐Apoa5 cells. (L) Relative mRNA expression levels (qPCR) of cholesterol transporter Abcg1 in LLC control, sgApoa5, and OE‐Apoa5 cells. (M‐O) Total cholesterol levels measured in (M) LLC cell lines (Control, sgApoa5, OE‐Apoa5, OE‐Apoa5/sgApoa5), (N) tumor epithelial cells derived from these cell lines’ mouse models, and (O) serum from C57BL/6J mice bearing these LLC tumors. (P) Intracellular cholesterol concentrations in WT and sgAapoa5 LLC cells treated with vehicle, lovastatin (Lova), or lovastatin together with cholesterol (Lova + Chol). (Q) Relative <t>Mif</t> mRNA levels in WT and sgApoa5 LLC cells following the indicated treatments with lovastatin alone or lovastatin plus cholesterol. (R) MIF concentration in the culture supernatants of WT and sgApoa5 LLC cells following the indicated treatments, as determined by ELISA. (S) Schematic model summarizing the proposed role of APOA5 in regulating cholesterol within tumor cells. (T) Western blot analysis validating APOA5 protein levels in LLC cells: Ctr (control), sg1 and sg2 (Apoa5 knockout using two different sgRNAs), OE (Apoa5 overexpression), Ctr (control for OE/sg1, OE/sg2 comparison), OE/sg1 and OE/sg2 (Apoa5 knockout in Apoa5 overexpressing cells). β‐actin was used as a loading control. (U) Representative images of LLC tumors harvested from C57BL/6J mice on day 21 post‐implantation with Control, sgApoa5 (LLC‐sgApoa5), OE‐Apoa5 (LLC‐OE‐Apoa5), or OE‐Apoa5/sgApoa5 (LLC‐OE‐Apoa5/sgApoa5) cells. (V) Tumor growth curves for the different LLC cell lines implanted in C57BL/6J mice (n = 5 mice per group). P‐values indicated compare each group to the Control.
Lamp Product, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/product+no/NEBuffer+r2%2E1/pmc13763177-137-3-9
Average 99 stars, based on 1 article reviews
lamp product - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

96
OriGene control sirna sr30004
APOA5 deficiency results in increased <t>intracellular</t> <t>cholesterol</t> and accelerated tumor progression. (A) Schematic overview of cholesterol homeostasis in a tumor cell, highlighting cholesterol synthesis (HMGCR, HMGCS1, NSDHL), esterification (ACAT1) and efflux (ABCG1). (B) Violin plot comparing cholesterol synthesis flux (determined by flux balance analysis) between TCGA‐LUAD samples with high versus low APOA5 expression. (C‐D) Boxplots showing normalized single‐sample Gene Ste Enrichment Analysis (ssGSEA) scores for (C) cholesterol esterification and (D) cholesterol metabolism in LUAD samples, stratified by high versus low APOA5 expression. (E) Line plot illustrating cholesterol efflux activity scores across TCGA LUAD samples (n = 238) ranked by APOA5 expression level, comparing high versus low APOA5 groups (p = 0.0038). (F‐I) Box plots displaying normalized mRNA expression levels from TCGA‐LUAD patient samples for key cholesterol metabolism genes: (F) HMGCR (p = 4.4e‐05), (G) NSDHL (p = 0.01), (H) ACAT1 (p = 1.5e‐05), and (I) ABCG1 (p = 0.049), comparing low versus high APOA5 expression groups. (J) Relative mRNA expression levels, determined by qPCR, of cholesterol synthesis pathway genes (Hmgcs1, Hmgcr, Nsdhl) in LLC control cells, Apoa5 knockout cells (sgApoa5), and Apoa5 overexpressing cells (OE‐Apoa5). (K) Relative mRNA expression levels (qPCR) of cholesterol esterification gene Acat1 and cholesterol transporter Abca1 in LLC control, sgApoa5, and OE‐Apoa5 cells. (L) Relative mRNA expression levels (qPCR) of cholesterol transporter Abcg1 in LLC control, sgApoa5, and OE‐Apoa5 cells. (M‐O) Total cholesterol levels measured in (M) LLC cell lines (Control, sgApoa5, OE‐Apoa5, OE‐Apoa5/sgApoa5), (N) tumor epithelial cells derived from these cell lines’ mouse models, and (O) serum from C57BL/6J mice bearing these LLC tumors. (P) Intracellular cholesterol concentrations in WT and sgAapoa5 LLC cells treated with vehicle, lovastatin (Lova), or lovastatin together with cholesterol (Lova + Chol). (Q) Relative <t>Mif</t> mRNA levels in WT and sgApoa5 LLC cells following the indicated treatments with lovastatin alone or lovastatin plus cholesterol. (R) MIF concentration in the culture supernatants of WT and sgApoa5 LLC cells following the indicated treatments, as determined by ELISA. (S) Schematic model summarizing the proposed role of APOA5 in regulating cholesterol within tumor cells. (T) Western blot analysis validating APOA5 protein levels in LLC cells: Ctr (control), sg1 and sg2 (Apoa5 knockout using two different sgRNAs), OE (Apoa5 overexpression), Ctr (control for OE/sg1, OE/sg2 comparison), OE/sg1 and OE/sg2 (Apoa5 knockout in Apoa5 overexpressing cells). β‐actin was used as a loading control. (U) Representative images of LLC tumors harvested from C57BL/6J mice on day 21 post‐implantation with Control, sgApoa5 (LLC‐sgApoa5), OE‐Apoa5 (LLC‐OE‐Apoa5), or OE‐Apoa5/sgApoa5 (LLC‐OE‐Apoa5/sgApoa5) cells. (V) Tumor growth curves for the different LLC cell lines implanted in C57BL/6J mice (n = 5 mice per group). P‐values indicated compare each group to the Control.
Control Sirna Sr30004, supplied by OriGene, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/product+no/siRNA+Related+Product/pmc13746310-66-14-18
Average 96 stars, based on 1 article reviews
control sirna sr30004 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
PackGene Biotech lnc aav8 cag egfp
APOA5 deficiency results in increased <t>intracellular</t> <t>cholesterol</t> and accelerated tumor progression. (A) Schematic overview of cholesterol homeostasis in a tumor cell, highlighting cholesterol synthesis (HMGCR, HMGCS1, NSDHL), esterification (ACAT1) and efflux (ABCG1). (B) Violin plot comparing cholesterol synthesis flux (determined by flux balance analysis) between TCGA‐LUAD samples with high versus low APOA5 expression. (C‐D) Boxplots showing normalized single‐sample Gene Ste Enrichment Analysis (ssGSEA) scores for (C) cholesterol esterification and (D) cholesterol metabolism in LUAD samples, stratified by high versus low APOA5 expression. (E) Line plot illustrating cholesterol efflux activity scores across TCGA LUAD samples (n = 238) ranked by APOA5 expression level, comparing high versus low APOA5 groups (p = 0.0038). (F‐I) Box plots displaying normalized mRNA expression levels from TCGA‐LUAD patient samples for key cholesterol metabolism genes: (F) HMGCR (p = 4.4e‐05), (G) NSDHL (p = 0.01), (H) ACAT1 (p = 1.5e‐05), and (I) ABCG1 (p = 0.049), comparing low versus high APOA5 expression groups. (J) Relative mRNA expression levels, determined by qPCR, of cholesterol synthesis pathway genes (Hmgcs1, Hmgcr, Nsdhl) in LLC control cells, Apoa5 knockout cells (sgApoa5), and Apoa5 overexpressing cells (OE‐Apoa5). (K) Relative mRNA expression levels (qPCR) of cholesterol esterification gene Acat1 and cholesterol transporter Abca1 in LLC control, sgApoa5, and OE‐Apoa5 cells. (L) Relative mRNA expression levels (qPCR) of cholesterol transporter Abcg1 in LLC control, sgApoa5, and OE‐Apoa5 cells. (M‐O) Total cholesterol levels measured in (M) LLC cell lines (Control, sgApoa5, OE‐Apoa5, OE‐Apoa5/sgApoa5), (N) tumor epithelial cells derived from these cell lines’ mouse models, and (O) serum from C57BL/6J mice bearing these LLC tumors. (P) Intracellular cholesterol concentrations in WT and sgAapoa5 LLC cells treated with vehicle, lovastatin (Lova), or lovastatin together with cholesterol (Lova + Chol). (Q) Relative <t>Mif</t> mRNA levels in WT and sgApoa5 LLC cells following the indicated treatments with lovastatin alone or lovastatin plus cholesterol. (R) MIF concentration in the culture supernatants of WT and sgApoa5 LLC cells following the indicated treatments, as determined by ELISA. (S) Schematic model summarizing the proposed role of APOA5 in regulating cholesterol within tumor cells. (T) Western blot analysis validating APOA5 protein levels in LLC cells: Ctr (control), sg1 and sg2 (Apoa5 knockout using two different sgRNAs), OE (Apoa5 overexpression), Ctr (control for OE/sg1, OE/sg2 comparison), OE/sg1 and OE/sg2 (Apoa5 knockout in Apoa5 overexpressing cells). β‐actin was used as a loading control. (U) Representative images of LLC tumors harvested from C57BL/6J mice on day 21 post‐implantation with Control, sgApoa5 (LLC‐sgApoa5), OE‐Apoa5 (LLC‐OE‐Apoa5), or OE‐Apoa5/sgApoa5 (LLC‐OE‐Apoa5/sgApoa5) cells. (V) Tumor growth curves for the different LLC cell lines implanted in C57BL/6J mice (n = 5 mice per group). P‐values indicated compare each group to the Control.
Aav8 Cag Egfp, supplied by PackGene Biotech lnc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/product+no/AAV8+Vector+Production/pm42991277-60-26-30
Average 96 stars, based on 1 article reviews
aav8 cag egfp - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

95
ABclonal Biotechnology rabbit monoclonal antibody
APOA5 deficiency results in increased <t>intracellular</t> <t>cholesterol</t> and accelerated tumor progression. (A) Schematic overview of cholesterol homeostasis in a tumor cell, highlighting cholesterol synthesis (HMGCR, HMGCS1, NSDHL), esterification (ACAT1) and efflux (ABCG1). (B) Violin plot comparing cholesterol synthesis flux (determined by flux balance analysis) between TCGA‐LUAD samples with high versus low APOA5 expression. (C‐D) Boxplots showing normalized single‐sample Gene Ste Enrichment Analysis (ssGSEA) scores for (C) cholesterol esterification and (D) cholesterol metabolism in LUAD samples, stratified by high versus low APOA5 expression. (E) Line plot illustrating cholesterol efflux activity scores across TCGA LUAD samples (n = 238) ranked by APOA5 expression level, comparing high versus low APOA5 groups (p = 0.0038). (F‐I) Box plots displaying normalized mRNA expression levels from TCGA‐LUAD patient samples for key cholesterol metabolism genes: (F) HMGCR (p = 4.4e‐05), (G) NSDHL (p = 0.01), (H) ACAT1 (p = 1.5e‐05), and (I) ABCG1 (p = 0.049), comparing low versus high APOA5 expression groups. (J) Relative mRNA expression levels, determined by qPCR, of cholesterol synthesis pathway genes (Hmgcs1, Hmgcr, Nsdhl) in LLC control cells, Apoa5 knockout cells (sgApoa5), and Apoa5 overexpressing cells (OE‐Apoa5). (K) Relative mRNA expression levels (qPCR) of cholesterol esterification gene Acat1 and cholesterol transporter Abca1 in LLC control, sgApoa5, and OE‐Apoa5 cells. (L) Relative mRNA expression levels (qPCR) of cholesterol transporter Abcg1 in LLC control, sgApoa5, and OE‐Apoa5 cells. (M‐O) Total cholesterol levels measured in (M) LLC cell lines (Control, sgApoa5, OE‐Apoa5, OE‐Apoa5/sgApoa5), (N) tumor epithelial cells derived from these cell lines’ mouse models, and (O) serum from C57BL/6J mice bearing these LLC tumors. (P) Intracellular cholesterol concentrations in WT and sgAapoa5 LLC cells treated with vehicle, lovastatin (Lova), or lovastatin together with cholesterol (Lova + Chol). (Q) Relative <t>Mif</t> mRNA levels in WT and sgApoa5 LLC cells following the indicated treatments with lovastatin alone or lovastatin plus cholesterol. (R) MIF concentration in the culture supernatants of WT and sgApoa5 LLC cells following the indicated treatments, as determined by ELISA. (S) Schematic model summarizing the proposed role of APOA5 in regulating cholesterol within tumor cells. (T) Western blot analysis validating APOA5 protein levels in LLC cells: Ctr (control), sg1 and sg2 (Apoa5 knockout using two different sgRNAs), OE (Apoa5 overexpression), Ctr (control for OE/sg1, OE/sg2 comparison), OE/sg1 and OE/sg2 (Apoa5 knockout in Apoa5 overexpressing cells). β‐actin was used as a loading control. (U) Representative images of LLC tumors harvested from C57BL/6J mice on day 21 post‐implantation with Control, sgApoa5 (LLC‐sgApoa5), OE‐Apoa5 (LLC‐OE‐Apoa5), or OE‐Apoa5/sgApoa5 (LLC‐OE‐Apoa5/sgApoa5) cells. (V) Tumor growth curves for the different LLC cell lines implanted in C57BL/6J mice (n = 5 mice per group). P‐values indicated compare each group to the Control.
Rabbit Monoclonal Antibody, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/product+no/Rabbit+Monoclonal+Antibody+Production/pm42992648-82-1-14
Average 95 stars, based on 1 article reviews
rabbit monoclonal antibody - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

97
TargetMol l6020 natural product library
APOA5 deficiency results in increased <t>intracellular</t> <t>cholesterol</t> and accelerated tumor progression. (A) Schematic overview of cholesterol homeostasis in a tumor cell, highlighting cholesterol synthesis (HMGCR, HMGCS1, NSDHL), esterification (ACAT1) and efflux (ABCG1). (B) Violin plot comparing cholesterol synthesis flux (determined by flux balance analysis) between TCGA‐LUAD samples with high versus low APOA5 expression. (C‐D) Boxplots showing normalized single‐sample Gene Ste Enrichment Analysis (ssGSEA) scores for (C) cholesterol esterification and (D) cholesterol metabolism in LUAD samples, stratified by high versus low APOA5 expression. (E) Line plot illustrating cholesterol efflux activity scores across TCGA LUAD samples (n = 238) ranked by APOA5 expression level, comparing high versus low APOA5 groups (p = 0.0038). (F‐I) Box plots displaying normalized mRNA expression levels from TCGA‐LUAD patient samples for key cholesterol metabolism genes: (F) HMGCR (p = 4.4e‐05), (G) NSDHL (p = 0.01), (H) ACAT1 (p = 1.5e‐05), and (I) ABCG1 (p = 0.049), comparing low versus high APOA5 expression groups. (J) Relative mRNA expression levels, determined by qPCR, of cholesterol synthesis pathway genes (Hmgcs1, Hmgcr, Nsdhl) in LLC control cells, Apoa5 knockout cells (sgApoa5), and Apoa5 overexpressing cells (OE‐Apoa5). (K) Relative mRNA expression levels (qPCR) of cholesterol esterification gene Acat1 and cholesterol transporter Abca1 in LLC control, sgApoa5, and OE‐Apoa5 cells. (L) Relative mRNA expression levels (qPCR) of cholesterol transporter Abcg1 in LLC control, sgApoa5, and OE‐Apoa5 cells. (M‐O) Total cholesterol levels measured in (M) LLC cell lines (Control, sgApoa5, OE‐Apoa5, OE‐Apoa5/sgApoa5), (N) tumor epithelial cells derived from these cell lines’ mouse models, and (O) serum from C57BL/6J mice bearing these LLC tumors. (P) Intracellular cholesterol concentrations in WT and sgAapoa5 LLC cells treated with vehicle, lovastatin (Lova), or lovastatin together with cholesterol (Lova + Chol). (Q) Relative <t>Mif</t> mRNA levels in WT and sgApoa5 LLC cells following the indicated treatments with lovastatin alone or lovastatin plus cholesterol. (R) MIF concentration in the culture supernatants of WT and sgApoa5 LLC cells following the indicated treatments, as determined by ELISA. (S) Schematic model summarizing the proposed role of APOA5 in regulating cholesterol within tumor cells. (T) Western blot analysis validating APOA5 protein levels in LLC cells: Ctr (control), sg1 and sg2 (Apoa5 knockout using two different sgRNAs), OE (Apoa5 overexpression), Ctr (control for OE/sg1, OE/sg2 comparison), OE/sg1 and OE/sg2 (Apoa5 knockout in Apoa5 overexpressing cells). β‐actin was used as a loading control. (U) Representative images of LLC tumors harvested from C57BL/6J mice on day 21 post‐implantation with Control, sgApoa5 (LLC‐sgApoa5), OE‐Apoa5 (LLC‐OE‐Apoa5), or OE‐Apoa5/sgApoa5 (LLC‐OE‐Apoa5/sgApoa5) cells. (V) Tumor growth curves for the different LLC cell lines implanted in C57BL/6J mice (n = 5 mice per group). P‐values indicated compare each group to the Control.
L6020 Natural Product Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/product+no/Natural+Product+Library/pm42980443-82-2-1
Average 97 stars, based on 1 article reviews
l6020 natural product library - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

Image Search Results


APOA5 deficiency results in increased intracellular cholesterol and accelerated tumor progression. (A) Schematic overview of cholesterol homeostasis in a tumor cell, highlighting cholesterol synthesis (HMGCR, HMGCS1, NSDHL), esterification (ACAT1) and efflux (ABCG1). (B) Violin plot comparing cholesterol synthesis flux (determined by flux balance analysis) between TCGA‐LUAD samples with high versus low APOA5 expression. (C‐D) Boxplots showing normalized single‐sample Gene Ste Enrichment Analysis (ssGSEA) scores for (C) cholesterol esterification and (D) cholesterol metabolism in LUAD samples, stratified by high versus low APOA5 expression. (E) Line plot illustrating cholesterol efflux activity scores across TCGA LUAD samples (n = 238) ranked by APOA5 expression level, comparing high versus low APOA5 groups (p = 0.0038). (F‐I) Box plots displaying normalized mRNA expression levels from TCGA‐LUAD patient samples for key cholesterol metabolism genes: (F) HMGCR (p = 4.4e‐05), (G) NSDHL (p = 0.01), (H) ACAT1 (p = 1.5e‐05), and (I) ABCG1 (p = 0.049), comparing low versus high APOA5 expression groups. (J) Relative mRNA expression levels, determined by qPCR, of cholesterol synthesis pathway genes (Hmgcs1, Hmgcr, Nsdhl) in LLC control cells, Apoa5 knockout cells (sgApoa5), and Apoa5 overexpressing cells (OE‐Apoa5). (K) Relative mRNA expression levels (qPCR) of cholesterol esterification gene Acat1 and cholesterol transporter Abca1 in LLC control, sgApoa5, and OE‐Apoa5 cells. (L) Relative mRNA expression levels (qPCR) of cholesterol transporter Abcg1 in LLC control, sgApoa5, and OE‐Apoa5 cells. (M‐O) Total cholesterol levels measured in (M) LLC cell lines (Control, sgApoa5, OE‐Apoa5, OE‐Apoa5/sgApoa5), (N) tumor epithelial cells derived from these cell lines’ mouse models, and (O) serum from C57BL/6J mice bearing these LLC tumors. (P) Intracellular cholesterol concentrations in WT and sgAapoa5 LLC cells treated with vehicle, lovastatin (Lova), or lovastatin together with cholesterol (Lova + Chol). (Q) Relative Mif mRNA levels in WT and sgApoa5 LLC cells following the indicated treatments with lovastatin alone or lovastatin plus cholesterol. (R) MIF concentration in the culture supernatants of WT and sgApoa5 LLC cells following the indicated treatments, as determined by ELISA. (S) Schematic model summarizing the proposed role of APOA5 in regulating cholesterol within tumor cells. (T) Western blot analysis validating APOA5 protein levels in LLC cells: Ctr (control), sg1 and sg2 (Apoa5 knockout using two different sgRNAs), OE (Apoa5 overexpression), Ctr (control for OE/sg1, OE/sg2 comparison), OE/sg1 and OE/sg2 (Apoa5 knockout in Apoa5 overexpressing cells). β‐actin was used as a loading control. (U) Representative images of LLC tumors harvested from C57BL/6J mice on day 21 post‐implantation with Control, sgApoa5 (LLC‐sgApoa5), OE‐Apoa5 (LLC‐OE‐Apoa5), or OE‐Apoa5/sgApoa5 (LLC‐OE‐Apoa5/sgApoa5) cells. (V) Tumor growth curves for the different LLC cell lines implanted in C57BL/6J mice (n = 5 mice per group). P‐values indicated compare each group to the Control.

Journal: Advanced Science

Article Title: An APOA5‐Derived Signature Bridges Cholesterol Homeostasis to T‐Cell Exhaustion and Directs Lung Adenocarcinoma Immunotherapy Response

doi: 10.1002/advs.78660

Figure Lengend Snippet: APOA5 deficiency results in increased intracellular cholesterol and accelerated tumor progression. (A) Schematic overview of cholesterol homeostasis in a tumor cell, highlighting cholesterol synthesis (HMGCR, HMGCS1, NSDHL), esterification (ACAT1) and efflux (ABCG1). (B) Violin plot comparing cholesterol synthesis flux (determined by flux balance analysis) between TCGA‐LUAD samples with high versus low APOA5 expression. (C‐D) Boxplots showing normalized single‐sample Gene Ste Enrichment Analysis (ssGSEA) scores for (C) cholesterol esterification and (D) cholesterol metabolism in LUAD samples, stratified by high versus low APOA5 expression. (E) Line plot illustrating cholesterol efflux activity scores across TCGA LUAD samples (n = 238) ranked by APOA5 expression level, comparing high versus low APOA5 groups (p = 0.0038). (F‐I) Box plots displaying normalized mRNA expression levels from TCGA‐LUAD patient samples for key cholesterol metabolism genes: (F) HMGCR (p = 4.4e‐05), (G) NSDHL (p = 0.01), (H) ACAT1 (p = 1.5e‐05), and (I) ABCG1 (p = 0.049), comparing low versus high APOA5 expression groups. (J) Relative mRNA expression levels, determined by qPCR, of cholesterol synthesis pathway genes (Hmgcs1, Hmgcr, Nsdhl) in LLC control cells, Apoa5 knockout cells (sgApoa5), and Apoa5 overexpressing cells (OE‐Apoa5). (K) Relative mRNA expression levels (qPCR) of cholesterol esterification gene Acat1 and cholesterol transporter Abca1 in LLC control, sgApoa5, and OE‐Apoa5 cells. (L) Relative mRNA expression levels (qPCR) of cholesterol transporter Abcg1 in LLC control, sgApoa5, and OE‐Apoa5 cells. (M‐O) Total cholesterol levels measured in (M) LLC cell lines (Control, sgApoa5, OE‐Apoa5, OE‐Apoa5/sgApoa5), (N) tumor epithelial cells derived from these cell lines’ mouse models, and (O) serum from C57BL/6J mice bearing these LLC tumors. (P) Intracellular cholesterol concentrations in WT and sgAapoa5 LLC cells treated with vehicle, lovastatin (Lova), or lovastatin together with cholesterol (Lova + Chol). (Q) Relative Mif mRNA levels in WT and sgApoa5 LLC cells following the indicated treatments with lovastatin alone or lovastatin plus cholesterol. (R) MIF concentration in the culture supernatants of WT and sgApoa5 LLC cells following the indicated treatments, as determined by ELISA. (S) Schematic model summarizing the proposed role of APOA5 in regulating cholesterol within tumor cells. (T) Western blot analysis validating APOA5 protein levels in LLC cells: Ctr (control), sg1 and sg2 (Apoa5 knockout using two different sgRNAs), OE (Apoa5 overexpression), Ctr (control for OE/sg1, OE/sg2 comparison), OE/sg1 and OE/sg2 (Apoa5 knockout in Apoa5 overexpressing cells). β‐actin was used as a loading control. (U) Representative images of LLC tumors harvested from C57BL/6J mice on day 21 post‐implantation with Control, sgApoa5 (LLC‐sgApoa5), OE‐Apoa5 (LLC‐OE‐Apoa5), or OE‐Apoa5/sgApoa5 (LLC‐OE‐Apoa5/sgApoa5) cells. (V) Tumor growth curves for the different LLC cell lines implanted in C57BL/6J mice (n = 5 mice per group). P‐values indicated compare each group to the Control.

Article Snippet: To investigate whether altered cholesterol levels contribute to the increased MIF production following Apoa5 depletion, control and Apoa5‐deficient (sgApoa5) Lewis lung carcinoma (LLC) cells were assigned to four groups: wild‐type control, sgApoa5, sgApoa5 treated with lovastatin, and sgApoa5 treated with lovastatin (MedChemExpress, HY‐N0504) plus water‐soluble cholesterol (MedChemExpress, HY‐N0322A).

Techniques: Analysis, Expressing, Activity Assay, Control, Knock-Out, Derivative Assay, Concentration Assay, Enzyme-linked Immunosorbent Assay, Western Blot, Over Expression, Comparison

APOA5 deficiency impairs T‐cells function in LUAD. (A) UMAP overview of the integrated single‐cell LUAD datasets (n = 42 patients; 118 730 cells). (B) UMAP visualization of major cell populations. (C) Malignant tumor cells classified as APOA5‐low or APOA5‐high according to APOA5 expression. (D) GSEA showing enrichment of cholesterol homeostasis in APOA5‐low malignant cells. (E) Expression of genes involved in cholesterol synthesis, esterification, and efflux in APOA5‐low and APOA5‐high malignant cells. (F) UMAP projection of T‐cell subclusters. (G) Chord diagram depicting predicted interactions between APOA5‐low tumor cells and T‐cell subclusters. (H) Dot plot of ligand‐receptor interactions from APOA5‐low malignant tumor cells to T‐cell subclusters, highlighting MIF‐CD74/CXCR4 signaling. (I) MIF mRNA expression in APOA5‐low versus APOA5‐high human malignant tumor cells. (J) ELISA quantification of secreted MIF in conditioned media from Control, OE‐Apoa5, OE‐Apoa5/sgApoa5, and sgApoa5 LLC cells. (K,L) Relative MFI values for PD‐1 (K) and TIM‐3 (L) in T cells co‐cultured with Control cells, sgApoa5 cells, or sgApoa5 cells in the presence of a CXCR4 inhibitor. (M–P) Representative flow cytometry histograms and corresponding mean fluorescence intensity (MFI) values for PD‐1 (M,N) and granzyme B (GZMB; (O,P)) in T cells under the indicated co‐culture conditions: Control, sgApoa5, sgApoa5/sgMif, and sgApoa5/sgMif supplemented with recombinant MIF (rMIF).

Journal: Advanced Science

Article Title: An APOA5‐Derived Signature Bridges Cholesterol Homeostasis to T‐Cell Exhaustion and Directs Lung Adenocarcinoma Immunotherapy Response

doi: 10.1002/advs.78660

Figure Lengend Snippet: APOA5 deficiency impairs T‐cells function in LUAD. (A) UMAP overview of the integrated single‐cell LUAD datasets (n = 42 patients; 118 730 cells). (B) UMAP visualization of major cell populations. (C) Malignant tumor cells classified as APOA5‐low or APOA5‐high according to APOA5 expression. (D) GSEA showing enrichment of cholesterol homeostasis in APOA5‐low malignant cells. (E) Expression of genes involved in cholesterol synthesis, esterification, and efflux in APOA5‐low and APOA5‐high malignant cells. (F) UMAP projection of T‐cell subclusters. (G) Chord diagram depicting predicted interactions between APOA5‐low tumor cells and T‐cell subclusters. (H) Dot plot of ligand‐receptor interactions from APOA5‐low malignant tumor cells to T‐cell subclusters, highlighting MIF‐CD74/CXCR4 signaling. (I) MIF mRNA expression in APOA5‐low versus APOA5‐high human malignant tumor cells. (J) ELISA quantification of secreted MIF in conditioned media from Control, OE‐Apoa5, OE‐Apoa5/sgApoa5, and sgApoa5 LLC cells. (K,L) Relative MFI values for PD‐1 (K) and TIM‐3 (L) in T cells co‐cultured with Control cells, sgApoa5 cells, or sgApoa5 cells in the presence of a CXCR4 inhibitor. (M–P) Representative flow cytometry histograms and corresponding mean fluorescence intensity (MFI) values for PD‐1 (M,N) and granzyme B (GZMB; (O,P)) in T cells under the indicated co‐culture conditions: Control, sgApoa5, sgApoa5/sgMif, and sgApoa5/sgMif supplemented with recombinant MIF (rMIF).

Article Snippet: To investigate whether altered cholesterol levels contribute to the increased MIF production following Apoa5 depletion, control and Apoa5‐deficient (sgApoa5) Lewis lung carcinoma (LLC) cells were assigned to four groups: wild‐type control, sgApoa5, sgApoa5 treated with lovastatin, and sgApoa5 treated with lovastatin (MedChemExpress, HY‐N0504) plus water‐soluble cholesterol (MedChemExpress, HY‐N0322A).

Techniques: Single Cell, Expressing, Enzyme-linked Immunosorbent Assay, Control, Cell Culture, Flow Cytometry, Fluorescence, Co-culture Assay, Recombinant

ACTsig links APOA5‐associated T‐cell states with prognosis and immunotherapy response in LUAD. (A) Heatmap showing immune programs across cytotoxic, transitional, and exhausted T‐cell states. (B) Venn diagrams identifying APOA5‐associated cytotoxic and exhausted T‐cell genes. (C) Consensus feature selection using Logistic Regression, Elastic Net, XGBoost, and Boruta Random Forest. (D) Performance ranking of 101 survival machine‐learning models, showing RSF as the optimal ACTsig modeling strategy. (E) Correlation between ACTsig genes and MIF expression. (F) MIF expression in ACTsig‐high and ACTsig‐low groups. (G) Pathway activity differences between ACTsig‐high and ACTsig‐low tumors. (H) Radar plot summarizing associations between ACTsig and immune/metabolic pathway activity. (I) Kaplan‐Meier analysis of progression‐free survival in an immunotherapy‐treated cohort stratified by ACTsig. (J) Immune‐checkpoint gene expression in ACTsig‐high and ACTsig‐low groups. (K) ACTsig scores in anti‐PD‐1 responders and non‐responders. (L) Response‐rate comparison between ACTsig‐high and ACTsig‐low groups. ACTsig‐high tumors were enriched for immunotherapy responders.

Journal: Advanced Science

Article Title: An APOA5‐Derived Signature Bridges Cholesterol Homeostasis to T‐Cell Exhaustion and Directs Lung Adenocarcinoma Immunotherapy Response

doi: 10.1002/advs.78660

Figure Lengend Snippet: ACTsig links APOA5‐associated T‐cell states with prognosis and immunotherapy response in LUAD. (A) Heatmap showing immune programs across cytotoxic, transitional, and exhausted T‐cell states. (B) Venn diagrams identifying APOA5‐associated cytotoxic and exhausted T‐cell genes. (C) Consensus feature selection using Logistic Regression, Elastic Net, XGBoost, and Boruta Random Forest. (D) Performance ranking of 101 survival machine‐learning models, showing RSF as the optimal ACTsig modeling strategy. (E) Correlation between ACTsig genes and MIF expression. (F) MIF expression in ACTsig‐high and ACTsig‐low groups. (G) Pathway activity differences between ACTsig‐high and ACTsig‐low tumors. (H) Radar plot summarizing associations between ACTsig and immune/metabolic pathway activity. (I) Kaplan‐Meier analysis of progression‐free survival in an immunotherapy‐treated cohort stratified by ACTsig. (J) Immune‐checkpoint gene expression in ACTsig‐high and ACTsig‐low groups. (K) ACTsig scores in anti‐PD‐1 responders and non‐responders. (L) Response‐rate comparison between ACTsig‐high and ACTsig‐low groups. ACTsig‐high tumors were enriched for immunotherapy responders.

Article Snippet: To investigate whether altered cholesterol levels contribute to the increased MIF production following Apoa5 depletion, control and Apoa5‐deficient (sgApoa5) Lewis lung carcinoma (LLC) cells were assigned to four groups: wild‐type control, sgApoa5, sgApoa5 treated with lovastatin, and sgApoa5 treated with lovastatin (MedChemExpress, HY‐N0504) plus water‐soluble cholesterol (MedChemExpress, HY‐N0322A).

Techniques: Selection, Expressing, Activity Assay, Analysis, Gene Expression, Comparison